• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    NKGen Biotech, Inc. - Common Stock (NQ: NKGN )

    0.2453 -0.0101 (-3.95%)
    Streaming Delayed Price Updated: 2:23 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about NKGen Biotech, Inc. - Common Stock

    < Previous 1 2 3 Next >
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies
    Via Get News
    Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies
    --News Direct-- 
    Via News Direct
    Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies
    New York, Feb 7, 2024 - (Plato Data) - On Thursday February 2, 2024, the bio industry welcomed the parliament’s passage of a bill that adds regenerative medicine organizations to the list of those... 
    Via TheNewswire.com
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    We're starting off trading on Tuesday with a look into the biggest pre-market stock movers traders need to keep an eye on today! 
    Via InvestorPlace
    NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial
    Via Get News
    NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial
    SANTA ANA, Calif., Dec. 29, 2023 - (Plato / Amplifi via 500NewsWire) -- NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient... 
    Via TheNewswire.com
    NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial
    --News Direct-- 
    Via News Direct
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Why Barnes Group Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Gainers Apollomics, Inc. (NASDAQ: APLM) shares surged 88.4% to $1.07 stoma multiforme with PTPRZ-MET fusion. 
    Via Benzinga
    Why Is PTC Therapeutics (PTCT) Stock Down 23% Today?
    PTC Therapeutics stock is falling on Friday as PTCT investors react to the company's lackluster earnings report for Q3 2023. 
    Via InvestorPlace
    Why Is TransCode Therapeutics (RNAZ) Stock Down 25% Today?
    TransCode Therapeutics stock is falling on Friday after the company announced plans for a public offering of RNAZ shares. 
    Via InvestorPlace
    Why Intel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
    Gainers NKGen Biotech, Inc. (NASDAQ: NKGN) shares surged 60.9% to $6.08 in pre-market trading after gaining 8% on Thursday. NKGen Biotech presented Phase I clinical trial data at the 16th Annual... 
    Via Benzinga
    Why Is Apollomics (APLM) Stock Up 113% Today?
    Apollomics stock is taking off on Friday with heavy trading of APLM following its latest study news presented to traders yesterday. 
    Via InvestorPlace
    Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
    NKGen Biotech stock is taking off on Friday as NKGN investors react to the company's clinical trial results for its Alzheimer’s treatment. 
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    It's time to start off the final trading day this week with a breakdown of the biggest pre-market stock movers on Friday! 
    Via InvestorPlace
    NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.
    Via Get News
    Exposures Product Safety
    NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.
    --News Direct-- 
    Via News Direct
    Exposures Product Safety
    NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.
    SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics,... 
    Via TheNewswire.com
    Exposures Product Safety
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday! 
    Via InvestorPlace
    Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent... 
    Via Benzinga
    Why Orchard Therapeutics Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving Premarket
    Gainers 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Pre-market stock movers are rising and falling on Thursday as we check out all of the latest news worth knowing about this morning! 
    Via InvestorPlace
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.